Showing 3641-3650 of 5258 results for "".
- First AD Patient Dosed in Lynk Pharmaceuticals' Phase Ib Clinical Study of Topical JAK Inhibitorhttps://practicaldermatology.com/news/first-ad-patient-dosed-in-lynk-pharmaceuticals-phase-ib-clinical-study-of-topical-jak-inhibitor/2461881/The first atopic dermatitis (AD) patient has been dosed in a Phase Ib clinical trial of LNK01004, Lynk Pharmaceuticals Co., Ltd. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LNK01004 ointment in Chinese patient
- MRA Announces 2023 Dermatology Fellowship Award Recipientshttps://practicaldermatology.com/news/mra-announces-2023-dermatology-fellowship-award-recipients/2461878/The Melanoma Research Alliance (MRA) has announced its 2023 Dermatology Fellowship Award recipients. The awardees will each receive a $50,000 grant to support an independent research project focused on advancing melanoma prevention or detection. Along with critical finan
- Revealed: Why Skin Gets 'Leathery' After Too Much Sunhttps://practicaldermatology.com/news/revealed-why-skin-gets-leathery-after-too-much-sun/2461875/When exposed to too much ultraviolet radiation, collagen fibers become more tightly packed together, according to research in the Journal of the Mechanical Behavior of Biomedical Mate
- Hoth Therapeutics Receives Protocol Approval for HT-001https://practicaldermatology.com/news/hoth-therapeutics-receives-protocol-approval-for-ht-001/2461873/Hoth Therapeutics, Inc. received approval from the Food & Drug Administration (FDA) for a protocol change in its Phase 2a clinical trial of HT-001. Participants will apply HT-001 Gel once per day for six weeks, during which the effect on treating acneiform rash and other skin
- Venus Concept Announces Medical Advisory Board for AI.ME, Its Next Generation Robotic Platformhttps://practicaldermatology.com/news/venus-concept-announces-medical-advisory-board-for-aime-its-next-generation-robotic-platform/2461872/Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technolo
- FDA Clears Xstrahl’s Radiant Aura for NMSCshttps://practicaldermatology.com/news/fda-clears-radiant-aura-receives-us-food-and-drug-administration-fda-510k-clearance/2461871/The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Xstrahl’s Radiant Aura, an office-based radiation therapy for non-melanoma skin cancer (NMSC). “We developed Radiant Aura to deliver both electronic brachytherapy and superficial radiation therapy in
- Warts and All: Novan Files Chapter 11, Sells Assetshttps://practicaldermatology.com/news/warts-and-all-novan-files-chapter-11-sells-assets/2461870/Novan is selling all of its assets, including Berdazimer Gel, 10.3% (SB206), and has filed for Chapter 11 Protection. The Company entered into a stalking horse asset purchase agreement (APA) with Ligand Pharmaceuticals, Inc. prior to filing voluntary petitions for relief unde
- Acclaro Medical Rebrands UltraClear Cold Fiber Laserhttps://practicaldermatology.com/news/acclaro-medical-rebrands-ultraclear-cold-fiber-laser/2461866/Meet the newly re-branded UltraClear Cold Fiber Laser from Acclaro Medical. From a design perspective, rebranding encompasses an updated logo and color palette and aims to increase recognition of UltraClear's 3DIntelliPulse technology and its ability to provide optima
- Revian Red Hair Growth System Takes on CCCA in Second Studyhttps://practicaldermatology.com/news/revian-red-hair-growth-system-takes-on-ccca-in-second-study/2461864/Revian Red Hair Growth System is planning a second study to build on previous trial results as an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). The Revian Red Hair Growth System is a US Foof and Drug Administration- cleared, lightweight wirel
- Study: DermaSensor Correctly Identifies 96.2% of Melanomas in Senior Citizenshttps://practicaldermatology.com/news/study-dermasensor-correctly-identifies-962-of-melanomas-in-senior-citizens/2461863/DermaSensor correctly identified 96.2% of melanomas in patients 65 and older, according to a sub-analysis of the DERM-ASSESS III study data of Medicare-eligible patients that was presented at the Annual American Dermoscopy Meeting. The sensitivity of the DermaSensor device for melanoma